C8orf47 Inhibitors

C8orf47 inhibitors encompass a range of chemical compounds that act on specific signaling pathways, with the end result being a decrease in C8orf47 activity. The primary pathways targeted by these inhibitors include the PI3K/AKT, JNK, p38 MAPK, and MEK/ERK pathways. A majority of these compounds, such as resveratrol, LY294002, quercetin, genistein, wortmannin, apigenin, and EGCG, act on the PI3K/AKT pathway, a critical signaling pathway that C8orf47 is thought to interact with. By inhibiting this pathway, these compounds can effectively reduce the functional activity of C8orf47.

Other inhibitors target different but related pathways. For example, curcumin and SP600125 hinder the JNK and p38 MAPK pathways. Simultaneously, SB203580 acts on the p38 MAPK pathway, and PD98059 and U0126 inhibit the MAPK and MEK/ERK pathways, respectively. These pathways are believed to intersect with C8orf47's functional mechanisms. Consequently, these inhibitors can indirectly reduce C8orf47 activity by dampening the signaling pathways it is involved with.